ACRS vs THQ Comparison

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. Its investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies. The fund invests in equity and debt securities of public and private healthcare companies believed by the Fund's Adviser to have potential for above-average growth, and may invest in private companies and other restricted securities, including private investments in public equity and venture capital investments, provided these securities comprise 10% or less of Managed Assets.